Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Revolution Medicines (RVMD)
NASDAQ:RVMD
Holding RVMD?
Track your performance easily
RVMD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$18.00 - $51.00
Previous Close$46.42
Volume2.08M
Average Volume (3M)1.02M
Market Cap
$7.75B
Enterprise Value$6.25B
Total Cash (Recent Filing)$1.59B
Total Debt (Recent Filing)$87.41M
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Nov 04, 2024EPS Estimate
-$0.89Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.65
Shares Outstanding167,038,943
10 Day Avg. Volume1,238,189
30 Day Avg. Volume1,024,890
Standard Deviation0.17
R-Squared0.21
Alpha0.00049
Financial Highlights & Ratios
Price to Book (P/B)4.83
Price to Sales (P/S)10450.06
Price to Cash Flow (P/CF)-15.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.42K
Enterprise Value/Gross Profit539.78
Enterprise Value/Ebitda-12.55
Forecast
1Y Price Target
$56.10Price Target Upside20.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Revolution Medicines News
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementsRMC-6236 demonstrates a meaningful improvement over standard chemotherapy in second-line treatments for pancreatic ductal adenocarcinoma, suggesting a promising alternative for patients with RAS mutations.
Financial PerformanceRevolution Medicines ended 2Q24 with approximately $1.59 billion in cash and cash equivalents, providing a strong financial foundation and operational runway into 2027, supporting key data developments and potential growth.
Investor OutlookInvestor expectations are high for RMC-9805 to show competitive efficacy across multiple tumor types, potentially leading to significant stock upside and increased market interest.
Bears Say
Competitive DataA 20% downside is expected if RMC-9805 data is not competitive in any tumors.
Financial RisksRisks include, but are not limited to: clinical setbacks with RMC-4630; inability to secure timely regulatory approval for RMC-4630; poorer-than-anticipated RMC-4630 sales performance; failures with other pipeline candidates, notably the RAS(ON) inhibitors; and possible long-term dilution risk.
Safety ProfileThe safety profile worsened on the margin from the prior update with higher rates of adverse events.
---
Ownership Overview
6.24% Insiders
27.06% Mutual Funds
0.28% Other Institutional Investors
50.85% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RVMD FAQ
What was Revolution Medicines’s price range in the past 12 months?
Revolution Medicines lowest stock price was $18.00 and its highest was $51.00 in the past 12 months.
What is Revolution Medicines’s market cap?
Currently, no data Available
When is Revolution Medicines’s upcoming earnings report date?
Revolution Medicines’s upcoming earnings report date is Nov 04, 2024 which is 6 days ago.
How were Revolution Medicines’s earnings last quarter?
Revolution Medicines released its earnings results on Aug 07, 2024. The company reported -$0.81 earnings per share for the quarter, missing the consensus estimate of -$0.775 by -$0.035.
Is Revolution Medicines overvalued?
According to Wall Street analysts Revolution Medicines’s price is currently Undervalued.
Does Revolution Medicines pay dividends?
Revolution Medicines does not currently pay dividends.
What is Revolution Medicines’s EPS estimate?
Revolution Medicines’s EPS estimate is -$0.89.
How many shares outstanding does Revolution Medicines have?
Revolution Medicines has 167,038,940 shares outstanding.
What happened to Revolution Medicines’s price movement after its last earnings report?
Revolution Medicines reported an EPS of -$0.81 in its last earnings report, missing expectations of -$0.775. Following the earnings report the stock price went down -0.686%.
Which hedge fund is a major shareholder of Revolution Medicines?
Among the largest hedge funds holding Revolution Medicines’s share is Farallon Capital Management, L.L.C.. It holds Revolution Medicines’s shares valued at 379M.
---
Revolution Medicines Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$56.10 (20.85% Upside)
$56.10 (20.85% Upside)
Blogger Sentiment
Bullish
RVMD Sentiment 66%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
131.98%
12-Months-Change
Fundamentals
Return on Equity
-40.73%
Trailing 12-Months
Asset Growth
68.43%
Trailing 12-Months
Company Description
Revolution Medicines
Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.
---
RVMD Earnings Call
Q2 2024
0:00 / 0:00
---
RVMD Stock 12 Month Forecast
Average Price Target
$56.10
▲(20.85% Upside)
Technical Analysis
Best Analysts Covering RVMD
1 Year
1 Year Success Rate
11/11 ratings generated profit
1 Year Average Return
+39.93%
reiterated a buy rating 3 months ago
Copying Benjamin Burnett's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +39.93% per trade.
---